Hypertension Management Guidelines

Introduction to Hypertension Management

• The American Diabetes Association recommends blood pressure measurement at every visit, with a target blood pressure of <130/80 mmHg for most patients with diabetes or high cardiovascular risk 1.
• The American Heart Association suggests that blood pressure should be measured at every visit, with a target blood pressure of <140/90 mmHg for lower-risk patients 2.

Blood Pressure Assessment and Diagnosis

• Blood pressure is measured at every visit, with a target blood pressure of <130/80 mmHg for most patients with diabetes or high cardiovascular risk 1.
• Confirmed hypertension diagnosis is made with readings ≥130/80 mmHg on separate occasions 1.
• Home blood pressure monitoring confirms sustained hypertension (≥135/85 mmHg average) 2.
• Orthostatic blood pressure is checked to assess for autonomic neuropathy (particularly in diabetic patients) 3.

Comorbidity Assessment

• Diabetes mellitus: Check urine albumin-to-creatinine ratio if diabetes is present 4, 1.
• Chronic kidney disease: Check current eGFR and urine albumin-to-creatinine ratio 4.
• Coronary artery disease: Assess for presence of coronary artery disease 2.
• Heart failure: Check for presence of heart failure and ejection fraction if present 2.
• Albuminuria: Check urine albumin-to-creatinine ratio if albuminuria is present 4, 1.

Blood Pressure Targets

• Target blood pressure: <130/80 mmHg for most patients with diabetes or high cardiovascular risk 4, 1.
• Target blood pressure: <140/90 mmHg minimum for lower-risk patients 2.

Lifestyle Modifications

• All patients receive comprehensive lifestyle therapy regardless of medication status 1.
• Sodium restriction: <1500 mg/day (or reduce by ≥1000 mg/day) 2.
• Potassium supplementation: 3500-5000 mg/day through diet 2.
• Weight loss: Target ≥1 kg reduction if overweight/obese 2.
• Physical activity: 90-150 minutes/week of aerobic exercise 2.
• Alcohol limitation: ≤2 drinks/day (men), ≤1 drink/day (women) 2.
• DASH diet: Emphasize fruits, vegetables, whole grains, low-fat dairy, and reduced saturated fat 2.

Pharmacologic Treatment Algorithm

Initial Monotherapy (BP 130-159/80-99 mmHg)

• For patients with diabetes AND albuminuria (UACR ≥30 mg/g): ACE inhibitor (e.g., lisinopril 10 mg daily) OR ARB (e.g., losartan 50 mg daily) at maximum tolerated dose 4, 1.
• For patients without albuminuria or diabetes: Start with thiazide-like diuretic (chlorthalidone 12.5-25 mg daily preferred over HCTZ), ACE inhibitor/ARB, OR calcium channel blocker (amlodipine 5-10 mg daily) 1.

Dual Therapy (BP not controlled on monotherapy)

• Standard combination for most patients: ACE inhibitor/ARB + calcium channel blocker (dihydropyridine) 1, 5.
• Alternative for Black patients or volume-dependent hypertension: Calcium channel blocker + thiazide-like diuretic 5, 6.

Prompt Dual Therapy (BP ≥160/100 mmHg)

• Initiate TWO drugs immediately or single-pill combination 4, 1.
• Preferred: ACE inhibitor/ARB + calcium channel blocker OR thiazide diuretic 1.

Triple Therapy (BP not controlled on dual therapy)

• Standard triple combination: ACE inhibitor/ARB + calcium channel blocker + thiazide-like diuretic 4, 1, 5.
• Example: Lisinopril 40 mg + amlodipine 10 mg + chlorthalidone 25 mg daily 5.

Resistant Hypertension (BP ≥140/90 on triple therapy)

• Before adding fourth agent, confirm: Medication adherence verified 1, white coat hypertension ruled out with home/ambulatory monitoring 1, and secondary causes excluded (primary aldosteronism, renal artery stenosis, sleep apnea) 1.
• Fourth-line agent: Add spironolactone 25-50 mg daily (preferred mineralocorticoid receptor antagonist) 4, 1, 7.
• Monitor potassium closely when combined with ACE inhibitor/ARB 4.

Monitoring Parameters

• Serum creatinine/eGFR and potassium: Check at baseline, 2-4 weeks after starting/titrating ACE inhibitor/ARB/diuretic, then annually 4, 1.
• Blood pressure reassessment: 2-4 weeks after medication initiation/adjustment 2, 1.
• Goal achievement timeline: Target BP within 3 months of treatment initiation/modification 2, 1.
• Annual monitoring: Blood pressure at every routine visit 3.

Medication Contraindications and Cautions

• Never combine ACE inhibitor + ARB (increases adverse events without benefit) 4, 1, 7.
• Avoid non-dihydropyridine calcium channel blockers (diltiazem/verapamil) in heart failure with reduced ejection fraction 2, 1.
• Beta-blockers only indicated for specific comorbidities (prior MI, angina, heart failure with reduced EF), not routine hypertension 1.
• Monitor for hyperkalemia when using ACE inhibitor/ARB, especially with eGFR <30 mL/min/1.73m² 4.

Specialist Referral Criteria

• Refer to hypertension specialist if: BP ≥140/90 mmHg despite four-drug therapy at optimal doses 4, 1, significant renal disease (eGFR <30 mL/min/1.73m²) 3, multiple drug intolerances 1, or suspected secondary hypertension 1.

Current Medications Prescribed

• [Medication name] [dose] [frequency] - [indication/rationale] [6].
• [Medication name] [dose] [frequency] - [indication/rationale] [6].

Follow-up Plan

• Return visit in [2-4 weeks/3 months] for BP recheck and medication titration 2, 1.
• Home BP monitoring log review at next visit 2.
• Laboratory monitoring (creatinine, potassium) scheduled for [date] [4].

First‑Line Antihypertensive Therapy for White Women with Primary Hypertension

Pharmacologic Options with Equivalent Efficacy

• In white women without comorbidities, four drug classes are considered equally effective as first‑line therapy: a thiazide‑like diuretic (chlorthalidone preferred), an ACE inhibitor, an ARB, or a dihydropyridine calcium‑channel blocker. The recommendation is based on the Diabetes Care guideline (2025) and no specific strength of evidence was reported. 8

Therapy Initiation Based on Blood‑Pressure Severity

• When the seated blood pressure is ≥150/90 mmHg, guidelines advise starting dual therapy immediately, using two agents from different classes to achieve target blood pressure more efficiently (Diabetes Care, 2025). No explicit evidence grade was provided. 8

Cardiovascular Outcome Data Across Drug Classes

• In patients lacking compelling indications (e.g., diabetes, coronary artery disease, chronic kidney disease), the four first‑line classes have shown equivalent reductions in cardiovascular events, supporting their interchangeable use (Diabetes Care, 2025). Evidence strength not specified. 8

Lifestyle Recommendation with Quantified BP Benefit

• The guideline cites that limiting alcohol intake to no more than one standard drink per day for women contributes to blood‑pressure control (Diabetes Care, 2025). No numerical effect size or evidence grade was given. 8

Contraindication Specific to Women of Child‑Bearing Potential

• ACE inhibitors and ARBs must be avoided in women of child‑bearing potential who are not using reliable contraception, because of teratogenic risk (Diabetes Care, 2025). The recommendation does not include an explicit strength of evidence. 8